GoKawiilNovartis and Bristol Myers Pause Autoimmune Drug Trials After Patient Deaths
Novartis and Bristol Myers Squibb have both suspended clinical trials of experimental autoimmune therapies after participants died or suffered life-threatening reactions. The companies are now investigating what caused the treatments, once seen as promising, to turn dangerous.
GoKawiil's interpretation of the reporting above, not reported fact.
Autoimmune drugs are a major growth area for pharma companies chasing alternatives to older immune-suppressing therapies, so safety setbacks here could slow a closely watched pipeline. Regulators and investors will be watching closely to see whether this points to a class-wide risk affecting similar drugs in development.
- Novartis and Bristol Myers halted separate autoimmune drug trials after serious adverse events.
- Some trial participants died or experienced life-threatening side effects.
- Companies are investigating the cause, raising questions about the broader safety of this treatment approach.
Source: wsj.com, 2026-09-03
Published there as: “Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.